Cystic Fibrosis in the PICU—More of a Zebra Than a Horse*

No abstract available
Source: Pediatric Critical Care Medicine - Category: Pediatrics Tags: Editorials Source Type: research

Related Links:

CONCLUSIONS: Given the very low quality of the evidence identified in this updated Cochrane Review we are uncertain whether any of the assessed pharmaceutical interventions reduce ulcer size or result in leg ulcer closure in treated participants compared to controls. However, this intervention was assessed as having a high risk of bias due to inadequacies in the single trial report. Other included studies were also assessed as having an unclear or high risk of bias. The harm profile of the all interventions remains inconclusive.PMID:34559425 | DOI:10.1002/14651858.CD008394.pub4
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research
As most cystic fibrosis (CF) patients progress to respiratory failure, lung functionality assessment is pivotal. We previously developed a test that indirectly monitors airways (inflammation/functional test) by measuring the spin-spin relaxation time (T2m) of the water hydrogens present in CF sputum. Here the T2m significance in the monitoring of CF lung disease was further investigated by studying the correlation of T2m with: 1) sputum viscoelasticity, 2) mucociliary clearability index (MCI)/cough clearability index (CCI) and 3) sputum average mesh-size.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Source Type: research
Conditions:   Cystic Fibrosis;   Covid19 Intervention:   Sponsors:   Medical University Innsbruck;   Queen's University, Belfast;   European Cystic Fibrosis Society - Clinical Trial Network;   Cystic Fibrosis Foundation Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Inhaled medicines (antibiotics and mucolytics) reduce the risk of exacerbations and slow lung function decline in cystic fibrosis [1,2]. However, real-world low adherence results in preventable morbidity and mortality [3 –7].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
The delivery of effective, high quality healthcare requires a combination of strong underpinning science, clinical measurement, diagnostic skills and the ability to empathetically interact with people who are vulnerable because of illness [1]. Over centuries we have built up ways of delivering healthcare through consultation, diagnosis and investigation and a relationship between the physician and patient delivered in community and hospitals settings [2]. In the majority of chronic conditions and particularly in the care of people with cystic fibrosis (CF) we have successfully developed sophisticated interdisciplinary inte...
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Editorial Source Type: research
ConclusionsOur study reveals unfavorable consequences of COVID-19 pandemic restrictions on PA of pwCF with unknown long-term consequences for their overall physical fitness and lung health. Strategies to overcome this undesirable situation are needed; increased uptake of telehealth PA programs and virtual exercise classes to promote PA participation might be one promising approach along with vaccination of pwCF and their close contacts.
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research
Condition:   Cystic Fibrosis Intervention:   Sponsor:   University Hospital, Motol Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material https://doi.org/10.23641/asha.16624366.PMID:34549989 | DOI:10.1044/2021_AJA-21-00031
Source: American Journal of Audiology - Category: Audiology Authors: Source Type: research
CONCLUSIONS: There is lack of evidence for the efficacy and safety of anti-IgE (omalizumab) therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis. There is a need for large prospective randomized controlled studies of anti-IgE therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis with both clinical and laboratory outcome measures such as steroid requirement, allergic bronchopulmonary aspergillosis exacerbations and lung function.PMID:34550603 | DOI:10.1002/14651858.CD010288.pub5
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research
Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material https://doi.org/10.23641/asha.16624366.PMID:34549989 | DOI:10.1044/2021_AJA-21-00031
Source: American Journal of Audiology - Category: Audiology Authors: Source Type: research
More News: Cystic Fibrosis | Pediatrics